Qilu Pharmaceutical
Qilu Pharmaceutical is a China-based pharmaceutical company running 20 late-stage cancer trials of QL1706, QLC5508 and QL2107 in non-small-cell lung cancer, oesophageal cancer and triple-negative breast cancer.
Overview
Qilu Pharmaceutical, based in Jinan, China, is a pharmaceutical company. Qilu Pharmaceutical is a large Chinese pharmaceutical manufacturer that develops and produces innovative drugs, biosimilars, improved new drugs and generic medicines across oncology, cardiovascular, anti-infection and ophthalmology, among other areas. On ClinicalTrials.gov it is the lead sponsor of 20 recruiting or active phase 2 and phase 3 interventional cancer trials (13 in phase 3), testing QL1706, QLC5508, QL2107, QL0911 and ESG401 in non-small-cell lung cancer, oesophageal cancer, triple-negative breast cancer, multiple myeloma and HR-positive / HER2-negative breast cancer. The largest, NCT06754644 (A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC), plans to enrol 808 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Scorecard
All companies- phase 3 +18
- phase 1/2 +1
- targets +4
- modalities +8
QLC5508 is an experimental antibody-drug conjugate from Qilu Pharmaceutical in phase 3 trials for oesophageal cancer, prostate cancer and non-small-cell lung cancer, aimed at B7-H3.
QL1706 is an experimental small-molecule drug from Qilu Pharmaceutical in phase 3 trials for non-small-cell lung cancer and colorectal cancer, with its target not yet stated publicly.
QL2107 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.
ESG401 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for triple-negative breast cancer and HR-positive / HER2-negative breast cancer, with its target not yet stated publicly.
QLS32015 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for multiple myeloma, with its target not yet stated publicly.
QLS31905 is an experimental investigational agent whose form is not stated in the registry from Qilu Pharmaceutical in phase 3 trials for pancreatic ductal adenocarcinoma, with its target not yet stated publicly.
QLH12016 is an experimental protein degrader from Qilu Pharmaceutical in phase 2 trials for prostate cancer, aimed at Androgen receptor.
Similar pages
not linked directly; found by shared links- CompanyMBrace Therapeutics
Shares Pancreatic ductal adenocarcinoma, Prostate cancer, Colorectal cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyShenzhen Ionova Life Sciences
Shares Pancreatic ductal adenocarcinoma, Prostate cancer, Colorectal cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyNanjing Leads Biolabs
Shares Oesophageal cancer, Multiple myeloma, Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyNuvation Bio
Shares Pancreatic ductal adenocarcinoma, Prostate cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyOncolytics Biotech
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-sponsor.
- CompanyOrion, Orion Pharma
Shares Pancreatic ductal adenocarcinoma, Prostate cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyOncoC4
Shares Prostate cancer, Colorectal cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyAP Biosciences
Shares Oesophageal cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.